Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04267055 · ClinicalTrials.gov registry record

DISSECT-N Post Market Data Collection Registry

A clinical trial of Thoracic Aortic Dissection, sponsored by Medtronic Cardiovascular.

Completed
Registry status
102
Enrollment target
20
Study locations

NCT04267055: Completed study of Thoracic Aortic Dissection, sponsored by Medtronic Cardiovascular.

NCT04267055 is a study of Thoracic Aortic Dissection that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 102 participants, below the 760-participant average among 5 other Thoracic Aortic Dissection trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04267055, a study of Thoracic Aortic Dissection, has completed, sponsored by Medtronic Cardiovascular.

COMPLETED
Registry status
102 participants
Enrollment target
20
Study locations

Study Summary

DISSECT-N is a post-market registry designed to assess real-world safety and effectiveness of Valiant Navion Thoracic Stent Graft System in the treatment of thoracic aortic dissections in real world practice.

Primary Outcome

Safety: Major Adverse Events (MAEs) Defined as: all-cause mortality (ACM), retrograde type A dissection (RTAD), aortic rupture, permanent paraplegia and paraparesis, stent induced new entry tear, conversion to open repair, disabling stroke, and non-preexisting renal failure. Effectiveness: Technical success defined as ability to advance, deploy and position the Valiant Navion Thoracic Stent Graft at target site with successful coverage and sealing of the proximal entry tear and removal of the d

Conditions Studied

Interventions

  • DEVICE Valiant Navion Thoracic Stent Graft System

Study Locations (20)

Other

  • Rigshospitalet - Copenhagen
  • General Hospital of Athens, Evaggelismos - Athens
  • Ospedale San Raffaele - Milano - Milan
  • Keio University Hospital - Tokyo
  • St. Antonius Ziekenhuis - Nieuwegein
  • Auckland City Hospital - Grafton
  • Narodny Ustav Srdcovych a Cievnych Chorob, A.S. - Bratislava

New York

  • Albany Medical Center - Albany
  • Northwell Health Lenox Hill Hospital - New York

Pennsylvania

  • UPMC Pinnacle Harrisburg Campus - Harrisburg
  • Hospital of the University of Pennsylvania - Philadelphia

Alabama

  • University of Alabama at Birmingham Hospital - Birmingham

Florida

  • University of Florida Health Shands Hospital - Gainesville

Georgia

  • Emory University Hospital - Atlanta

Michigan

  • University of Michigan Health System - University Hospital - Ann Arbor

North Carolina

  • Atrium Health's Carolinas Medical Center - Charlotte

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2020-06-25
Est. Completion 2024-07-05
Medtronic Cardiovascular

44 total trials

What the finished NCT04267055 record still lists

NCT04267055 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 760-participant average among 5 other Thoracic Aortic Dissection trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Thoracic Aortic Dissection appearing as the primary indexed condition, and to 1 intervention - of which Valiant Navion Thoracic Stent Graft System is the first listed.

NCT04267055 names 20 study sites across 12 states, led by Other, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04267055 about?

NCT04267055 is a clinical study titled "DISSECT-N Post Market Data Collection Registry". DISSECT-N is a post-market registry designed to assess real-world safety and effectiveness of Valiant Navion Thoracic Stent Graft System in the treatment of thoracic aortic dissections in real world practice.

What is the current status of trial NCT04267055?

This trial is currently completed. The enrollment target is 102 participants. The study started on 2020-06-25. Estimated completion is 2024-07-05.

What conditions does trial NCT04267055 study?

This clinical trial studies the following conditions: Thoracic Aortic Dissection.

What interventions are being tested in trial NCT04267055?

The interventions under investigation include: Valiant Navion Thoracic Stent Graft System (DEVICE).

Who is sponsoring clinical trial NCT04267055?

This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04267055 being conducted?

This trial has 20 study locations across Alabama, Florida, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thoracic Aortic Dissection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04267055, the US trial registry maintained by the National Library of Medicine. NCT04267055 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.